GSK (GSK) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed GSK (GSK) over the past year, gaining 33.0% versus a gain of 7.0%. Over five years, TAK leads with a +32.8% price change compared with +19.2% for GSK. GSK is the larger company by market cap ($93.16 billion vs $59.83 billion), about 1.6 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 35.3x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1067.81% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | TAK |
|---|---|---|
| Share price | $46.50 | $18.73 |
| Market cap | $93.16B | $59.83B |
| 1-day change | -0.09% | +1.13% |
| YTD return | -5.18% | +20.14% |
| 1-year return | +7.04% | +33.03% |
| 5-year return | +19.20% | +32.84% |
| P/E ratio (TTM) | 14.67 | — |
| Forward P/E | 9.41 | 35.34 |
| EPS (TTM) | $3.17 | $-0.34 |
| Dividend yield | 1.46% | 1067.81% |
| Annual dividend | $0.68 | $200.00 |
| 52-week high | $61.70 | $19.10 |
| 52-week low | $42.85 | $12.99 |
| Distance from 52-week high | -24.64% | -1.94% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +27.59% | +17.25% |
| Average volume | 3.94M | 3.05M |
| Shares outstanding | 2.00B | 3.19B |
| Employees | 66,841 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TAK has outperformed GSK by 26.0 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1067.81% vs 1.46%).
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
GSK vs TAK FAQ
Which is bigger, GSK or Takeda Pharmaceutical?
GSK (GSK) is larger, with a market capitalization of $93.16B compared with $59.83B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, GSK or TAK?
TAK returned +33.03% over the past 12 months, compared with +7.04% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, GSK or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 1067.81%, compared with 1.46% for GSK.
Are GSK and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.